MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory follicular lymphoma and B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor for B-cell malignancies and AML. In addition, the company engages in the development of ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex for the treatment of HER2-negative breast cancer. MEI Pharma, Inc. has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacture, and commercialization of Pracinosta